Ipamorelin is widely considered the cleanest GH secretagogue available in the research peptide space. Unlike older GHRPs such as GHRP-2 and GHRP-6, Ipamorelin stimulates GH release without meaningfully elevating cortisol, prolactin, or ACTH — the off-target effects that make other GHRPs less attractive for long-term use. This selectivity, combined with its reliable potency, has made it the default GHRP in most modern GH-focused research protocols.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Ipamorelin is primarily used as a growth hormone secretagogue — it triggers the pituitary to release GH in a pulsatile, physiological pattern. Research applications include body recomposition (increased lean mass, reduced fat), improved sleep quality and recovery, anti-aging (GH declines with age), and bone density. It's most commonly stacked with CJC-1295 (no DAC) for a synergistic GH pulse.
How Does Ipamorelin Work?
Ipamorelin is a pentapeptide (5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist of the ghrelin receptor (GHSR-1a) in the pituitary. By binding GHSR-1a, it mimics the natural ghrelin signal that triggers pulsatile GH release.
What distinguishes Ipamorelin from GHRP-2 and GHRP-6 is receptor selectivity. Older GHRPs activate GHSR-1a but also stimulate corticotroph cells (raising cortisol and ACTH) and lactotroph cells (raising prolactin). Ipamorelin's binding profile is sufficiently selective that it produces GH pulses with minimal cortisol or prolactin elevation in research settings — a cleaner hormonal signal.
When combined with a GHRH analog like CJC-1295 (no DAC), Ipamorelin produces a synergistically amplified GH pulse. GHRH analogs act on the GHRH receptor to set the amplitude of GH release; ghrelin mimetics like Ipamorelin act on GHSR-1a to trigger the pulse. Together they work on two separate receptor pathways simultaneously, producing a GH pulse substantially larger than either alone.
What the Research Shows
Ipamorelin was developed by Novo Nordisk in the late 1990s and characterised in several peer-reviewed publications. The key paper by Raun et al. (1998) in the European Journal of Endocrinology established its GH selectivity and compared it favorably to GHRP-6 and GHRP-2 on the cortisol and ACTH elevation issue.
In rat models, Ipamorelin has shown bone mineral density increases, muscle mass improvements, and fat reduction — effects consistent with elevated GH/IGF-1 signaling. Human research is limited but the pharmacological profile is well-characterised.
Community data from r/Peptides and related forums shows Ipamorelin's real-world use concentrated heavily in: sleep quality improvement (pre-sleep GH pulse augmentation), body recomposition, and general recovery enhancement. The clean side effect profile makes it a common first peptide for those new to GH secretagogues.
What Is the Recommended Ipamorelin Dosage?
| Protocol | Dose | Frequency | Timing |
|---|---|---|---|
| General recovery | 200 mcg | 1–2x daily | Pre-sleep + optionally pre-workout |
| Body recomposition | 200–300 mcg | 3x daily | AM fasted, pre-workout, pre-sleep |
| Sleep optimisation | 200–300 mcg | 1x daily | 30–60 min before sleep, fasted |
| Stacked with CJC-1295 | 200 mcg each | 2–3x daily | Same injection, fasted timing |
| Conservative start | 100 mcg | 1x daily | Pre-sleep |
Side Effects & Safety
Ipamorelin is well-tolerated at research doses with a notably cleaner side effect profile than GHRP-2 or GHRP-6.
**Water retention:** The most commonly reported side effect — transient fluid retention in the first 2–4 weeks as the body adapts to elevated GH/IGF-1. Usually resolves and is more pronounced at higher doses.
**GH flu:** Some users experience fatigue, joint aches, and mild lethargy in the first 1–2 weeks. Considered an adaptation response to elevated GH activity.
**Hunger (mild):** Ghrelin is an appetite-stimulating hormone, and Ipamorelin's ghrelin receptor activity can mildly increase appetite — much less than GHRP-6, which causes intense hunger. Usually not problematic at standard doses.
**No meaningful cortisol elevation:** Confirmed in the Raun et al. research and consistently reported by users. This is Ipamorelin's defining advantage over older GHRPs.
**Cycling:** Most protocols use 3–6 month cycles with 4–8 week breaks. Continuous use hasn't been studied long-term.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Ipamorelin is primarily used as a growth hormone secretagogue — it triggers the pituitary to release GH in a pulsatile, physiological pattern. Research applications include body recomposition (increased lean mass, reduced fat), improved sleep quality and recovery, anti-aging (GH declines with age), and bone density. It's most commonly stacked with CJC-1295 (no DAC) for a synergistic GH pulse.
All three are ghrelin receptor agonists, but Ipamorelin is significantly more selective. GHRP-2 and GHRP-6 both cause meaningful cortisol and prolactin elevation along with GH release. GHRP-6 also causes intense hunger. Ipamorelin produces comparable GH stimulation with minimal off-target hormonal effects, making it preferable for most research protocols where the goal is clean GH stimulation.
Without food — ideally fasted for at least 2 hours before injection. Elevated blood glucose and free fatty acids blunt GH release by increasing somatostatin secretion. Eating close to an injection substantially reduces the GH pulse. The pre-sleep injection is the most important: avoid eating 2 hours before bed for maximum effect.
CJC-1295 without DAC (Mod GRF 1-29) is the standard pairing. CJC-1295 acts on the GHRH receptor to amplify the GH pulse that Ipamorelin triggers via the ghrelin receptor. Together they produce a significantly larger, cleaner GH release than either alone. Dose both simultaneously in the same injection — same timing, same syringe.
The GH pulse begins within 15–30 minutes of injection and peaks around 30–60 minutes. Subjective effects on sleep quality often appear within the first 1–2 weeks. Body composition changes typically take 6–12 weeks of consistent use. IGF-1 elevation (the downstream anabolic signal) becomes measurable after several weeks on protocol.
Ipamorelin is used by women in research protocols. The GH-stimulating effects are generally considered beneficial regardless of sex, and the clean side effect profile (no significant cortisol, prolactin, or ACTH elevation) makes it more appropriate than older GHRPs. Lower doses (100–200 mcg vs 200–300 mcg) are commonly used in female protocols. No specific contraindications for women beyond general research peptide cautions.